Kelvin Chan, PhD

Dr. Kelvin Chan is an operator-investor with over a decade of experience across company building, investing, and research. He is currently CTO & CBO of Crafton Biotechnology, an oncology-focused mRNA company. Previously, Kelvin was part of the founding team at Kudo Biotechnology, an mRNA CDMO, where he led Commercial Strategy and Business Development. He held Director roles at ABio-X, a biotech incubator backed by CBC Group, and at RVAC Medicines, where his work focused on S&E, BD&L, partnership development, portfolio strategy, and execution of cross-border collaborations. Kelvin operated across portfolio companies within Tavistock, supporting M&A and strategic initiatives. He was a venture investor at EDBI, the investment arm of the Singapore Economic Development Board, where he led and participated in healthcare and life sciences investments, and supported portfolio companies through partnerships with industry and government stakeholders. He served as a Board observer for multiple companies. Kelvin initially trained as a drug discovery scientist. He received his PhD in Organic Chemistry from Scripps Research, with publications in Nature Chemistry and JACS. He conducted his postdoc at the Singapore Bioimaging Consortium (A*STAR) developing pre-clinical radiopharmaceuticals. He graduated from the University of Cambridge with a BA (First Class Honors) in Natural Sciences (Chemistry).